


CORRECTION

Open Access



Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Shigeo Muro^{1*} , Hisatoshi Sugiura², Patrick Darken³ and Paul Dorinsky⁴

Correction to: *Respir Res* (2021) 22:187

<https://doi.org/10.1186/s12931-021-01773-1>

The original version of this article unfortunately contained a mistake [1]. The minor correction of Table 1 was

missing. That is, the text 'FF' should be 'GFF'.
The correct Table 1 is given in this erratum.

The original article can be found online at <https://doi.org/10.1186/s12931-021-01773-1>.

*Correspondence: smuro@narmed-u.ac.jp

¹ Department of Respiratory Medicine, Nara Medical University Graduate School of Medicine, 840 Shijo-cho, Kashihara-shi, 634-8521 Nara, Japan
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Demographic and baseline disease characteristics (mITT population)

	BGF 320/14.4/10 µg		GFF 14.4/10 µg		BFF 320/10 µg		BUD/FORM 400/12 µg	
	Non-reversible and EOS < 300 ^b (n = 319)	Overall population (n = 639)	Non-reversible and EOS < 300 ^b (n = 315)	Overall population (n = 625)	Non-reversible and EOS < 300 ^b (n = 161)	Overall population (n = 314)	Non-reversible and EOS < 300 ^b (n = 153)	Overall population (n = 318)
Mean age, years (SD)	65.6 (7.5)	64.9 (7.8)	65.6 (7.6)	65.1 (7.7)	65.3 (7.2)	65.2 (7.2)	66.5 (7.5)	65.9 (7.7)
Male, n (%)	216 (67.7)	460 (72.0)	207 (65.7)	430 (68.8)	108 (67.1)	224 (71.3)	104 (68.0)	236 (74.2)
Mean CAT Score (SD)	18.4 (6.7)	18.7 (6.4)	18.2 (6.4)	18.1 (6.1)	18.5 (6.7)	18.4 (6.6)	17.6 (7.0)	18.0 (6.4)
Mean body mass index, kg/m ² (SD)	25.9 (6.9)	26.1 (6.7)	25.9 (6.5)	26.3 (6.4)	25.4 (5.4)	26.1 (5.8)	25.8 (6.0)	26.2 (6.3)
Current smoker, n (%)	123 (38.6)	256 (40.1)	132 (41.9)	257 (41.1)	61 (37.9)	115 (36.6)	64 (41.8)	122 (38.4)
Median number of pack-years smoked ^a (range)	45.0 (10–192.5)	45.0 (10.0–256.0)	45.0 (10.0–171.0)	45.0 (10.0–171.0)	47.0 (10.0–192.0)	45.0 (10.0–192.0)	45.8 (10.0–153.0)	45.0 (10.0–180.0)
Median EOS, cells/mm ³ (range)	130.0 (10.0–295.0)	150.0 (10.0–2815.0)	140.0 (15.0–295.0)	155.0 (15.0–2490.0)	125.0 (20.0–295.0)	152.5 (15.0–920.0)	140.0 (35.0–295.0)	150.0 (35.0–1100.0)
Exacerbation history, n (%)								
0	239 (74.9)	469 (73.4)	229 (72.7)	473 (75.7)	115 (71.4)	235 (74.8)	111 (72.5)	234 (73.6)
1	61 (19.1)	125 (19.6)	63 (20.0)	108 (17.3)	37 (23.0)	61 (19.4)	29 (19.0)	59 (18.6)
≥ 2	19 (6.0)	45 (7.0)	23 (7.3)	44 (7.0)	9 (5.6)	18 (5.7)	13 (8.5)	25 (7.9)
Post-bronchodilator FEV ₁ , % predicted (SD)	48.5 (15.1)	50.2 (14.3)	47.6 (14.3)	50.2 (13.8)	47.5 (14.4)	50.0 (14.0)	48.5 (14.0)	50.7 (13.8)
Mean reversibility, % (SD)	10.1 (8.7)	18.8 (14.4)	9.3 (9.0)	18.1 (14.3)	10.3 (9.4)	19.0 (16.5)	10.6 (8.2)	19.9 (15.1)
Use of ICS at screening, n (%)	220 (69.0)	464 (72.6)	226 (71.7)	447 (71.5)	117 (72.7)	225 (71.7)	107 (69.9)	225 (70.8)

Overall population data from [4]

BFF, budesonide/formoterol fumarate dihydrate; BGF, budesonide/glycopyrronium/formoterol fumarate dihydrate; BUD/FORM DPI, budesonide/formoterol fumarate dihydrate dry powder inhaler; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; EOS, blood eosinophil count; FEV₁, forced expiratory volume in 1 s; GFF, glycopyrronium/formoterol fumarate dihydrate; ICS, inhaled corticosteroid; MDI, metered dose inhaler; mITT, modified intent-to-treat; SD, standard deviation

^a Number of pack years smoked = (number of cigarettes per day/20) × number of years smoked

^b Patients with airways not reversible to albuterol and EOS < 300 cells/mm³

Author details

¹Department of Respiratory Medicine, Nara Medical University Graduate School of Medicine, 840 Shijo-cho, Kashihara-shi, 634-8521 Nara, Japan.

²Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. ³AstraZeneca, Wilmington, DE, USA. ⁴AstraZeneca, Durham, NC, USA.

Reference

- Muro S, Sugiura H, Darken P, Dorinsky P. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. *Respir Res.* 2021;22:187. <https://doi.org/10.1186/s12931-021-01773-1>.

Published online: 09 August 2021

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.